Document Detail

Cardiac toxicity from systemic cancer therapy: a comprehensive review.
MedLine Citation:
PMID:  20728696     Owner:  NLM     Status:  MEDLINE    
Cardiovascular toxicity is a potential short- or long-term complication of anticancer therapy. Exposure to chemotherapy medications, primarily the anthracycline class, can lead to potentially irreversible clinically significant cardiac dysfunction. The advent of novel biologic agents, including monoclonal antibodies and tyrosine kinase inhibitors, has revolutionized the treatment of several types of malignancies. Although targeted therapies are considered less toxic and better tolerated by patients compared with classic chemotherapy agents, rare serious complications have been observed; and longer-term follow-up is needed to determine the exact profile of related cardiac adverse effects. Cardiac toxicity associated with cancer therapies can range from asymptomatic subclinical abnormalities, including electrocardiographic changes and temporary left ventricular ejection fraction decline, to life-threatening events such as congestive heart failure or acute coronary syndromes. Assessment of the prevalence, type, and severity of cardiac toxicity caused by various cancer treatments is a critical topic for patient management and specifically for new drug development. Guidelines for monitoring cardiac adverse effects have been formulated; however, appropriate supportive evidence remains limited. Given the rate of new drug development designed to fulfill unmet oncologic needs, efforts are needed to promote strategies for cardiac risk detection and management and to avoid unintended consequences potentially impeding development of, regulatory approval for, and patient access to novel therapies. These advances require ongoing research to assess and manage the cardiovascular safety of patients treated with anticancer agents, as well as a well-organized collaboration between oncologists and cardiologists. The aim of this review is to summarize potential cardiovascular toxicities for a range of cancer chemotherapeutics and to review general mechanisms of cardiovascular toxicity for each agent.
Giuseppe Curigliano; Erica L Mayer; Harold J Burstein; Eric P Winer; Aron Goldhirsch
Related Documents :
2244376 - Medical management of congestive heart failure.
9654396 - Experimental cardiomyopathy as a model of chronic heart failure.
9684036 - Prognostic assessment of end-stage cardiac failure.
25212646 - Effect of aspiration thrombectomy on microvascular obstruction in nstemi patients: the ...
14667256 - Acute myocardial infarction from spontaneous coronary artery dissection a case report a...
1679976 - Silent ischemia and severity of pain in acute myocardial infarction.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Progress in cardiovascular diseases     Volume:  53     ISSN:  1873-1740     ISO Abbreviation:  Prog Cardiovasc Dis     Publication Date:    2010 Sep-Oct
Date Detail:
Created Date:  2010-08-23     Completed Date:  2010-09-27     Revised Date:  2013-05-02    
Medline Journal Info:
Nlm Unique ID:  0376442     Medline TA:  Prog Cardiovasc Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  94-104     Citation Subset:  AIM; IM    
Copyright Information:
Copyright 2010 Elsevier Inc. All rights reserved.
Division of Medical Oncology, Department of Medicine, Istituto Europeo di Oncologia, Miano, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / adverse effects*
Cooperative Behavior
Heart Diseases / chemically induced*,  diagnosis,  physiopathology,  prevention & control
Interdisciplinary Communication
Medical Oncology
Neoplasms / drug therapy*
Patient Care Team
Risk Assessment
Risk Factors
Reg. No./Substance:
0/Antineoplastic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The compelling need for a cardiology and oncology partnership and the birth of the International Car...
Next Document:  Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?